Profile data is unavailable for this security.
About the company
Chimerix, Inc. is a biotechnology company. The Company is focused on developing medicines that address unmet medical needs. The Company's product Imipridones is a cancer therapy that provides ONC201, which is in clinical-stage development for H3 K27M-mutant glioma as its lead indication. In addition, imipridone ONC206 is in dose-escalating clinical trials. Imipridones target specific G protein-coupled receptors (GPCRs) and mitochondrial caseinolytic protease P (ClpP), resulting in cancer cell death. The Company's product Imipridone chemical scaffold provides an opportunity to target GPCRs and ClpP with tunable specificity and modality, which enables therapeutic use for cancer and other diseases. Its ONC206 is an imipridone, Dopamine Receptor D2 (DRD2) antagonist and ClpP agonist. Its ONC212 is an imipridone, an investigational agonist of the orphan GPCR tumor suppressor GPR132, as well as ClpP. Its CMX521 is a nucleoside analog antiviral drug candidate for the treatment of SARS-CoV-2.
- Revenue in USD (TTM)324.00k
- Net income in USD-82.10m
- Incorporated2000
- Employees72.00
- LocationChimerix Inc2505 Meridian Parkway, Suite 100DURHAM 27713United StatesUSA
- Phone+1 (919) 806-1074
- Fax+1 (919) 806-1146
- Websitehttps://www.chimerix.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CEL-SCI Corp | 0.00 | -31.05m | 77.73m | 43.00 | -- | 5.69 | -- | -- | -0.6825 | -0.6825 | 0.00 | 0.2529 | 0.00 | -- | -- | -- | -84.76 | -70.19 | -97.55 | -78.31 | -- | -- | -- | -15,434.15 | 0.7822 | -42.08 | 0.4717 | -- | -- | -- | 13.99 | -- | 223.59 | -- |
| Tempest Therapeutics Inc | 0.00 | -29.49m | 78.56m | 17.00 | -- | 2.92 | -- | -- | -1.96 | -1.96 | 0.00 | 1.21 | 0.00 | -- | -- | 0.00 | -60.38 | -57.10 | -72.81 | -71.20 | -- | -- | -- | -- | -- | -87.30 | 0.2827 | -- | -- | -- | 17.41 | -- | 36.40 | -- |
| Spero Therapeutics Inc | 103.78m | 22.81m | 78.68m | 46.00 | 3.60 | 0.7239 | 3.39 | 0.7582 | 0.4055 | 0.4055 | 1.96 | 2.02 | 0.6757 | -- | 4.01 | 2,256,087.00 | 14.85 | -35.52 | 18.36 | -41.75 | -- | -- | 21.98 | -124.40 | -- | -- | 0.00 | -- | 93.95 | 92.11 | 149.14 | -- | -- | -- |
| Assertio Holdings Inc | 152.07m | -331.94m | 78.78m | 53.00 | -- | 0.5681 | -- | 0.5181 | -3.97 | -3.97 | 2.04 | 1.46 | 0.4343 | 1.04 | 3.27 | 2,869,227.00 | -94.80 | -21.51 | -129.77 | -32.05 | 82.36 | 88.68 | -218.28 | -62.10 | 1.43 | -- | 0.2182 | -- | -2.67 | -13.38 | -402.80 | -- | -28.25 | -- |
| LifeVantage Corp | 210.95m | 2.96m | 79.59m | 248.00 | 26.68 | 2.92 | 12.04 | 0.3773 | 0.2319 | 0.2319 | 16.51 | 2.12 | 3.23 | 2.43 | 88.97 | 850,604.80 | 4.54 | 11.65 | 7.04 | 18.92 | 79.65 | 82.20 | 1.40 | 3.42 | 1.03 | -- | 0.00 | 5.23 | 3.41 | 0.9838 | -18.59 | -18.77 | -7.98 | -- |
| Tiziana Life Sciences Ltd - ADR | 0.00 | -15.40m | 79.78m | 9.00 | -- | 4.08 | -- | -- | -0.1496 | -0.1496 | 0.00 | 0.1914 | 0.00 | -- | -- | 0.00 | -40.89 | -- | -50.40 | -- | -- | -- | -- | -- | -- | -2,083.71 | 0.0183 | -- | -- | -- | 34.25 | -- | -- | -- |
| Chimerix Inc | 324.00k | -82.10m | 80.28m | 72.00 | -- | 0.4146 | -- | 247.78 | -0.9267 | -0.9267 | 0.0037 | 2.17 | 0.0013 | -- | 0.6207 | 4,500.00 | -33.36 | -30.45 | -36.22 | -34.09 | 100.00 | -- | -25,337.96 | -442.93 | -- | -- | 0.00 | -- | -99.04 | -46.24 | -147.68 | -- | -13.24 | -- |
| vTv Therapeutics Inc | 0.00 | -20.25m | 81.17m | 16.00 | -- | -- | -- | -- | -9.79 | -9.79 | 0.00 | -9.27 | 0.00 | -- | -- | 0.00 | -117.34 | -111.84 | -1,613.30 | -- | -- | -- | -- | -680.94 | -- | -- | -- | -- | -100.00 | -- | -5.67 | -- | -- | -- |
| Passage Bio Inc | 0.00 | -102.06m | 81.33m | 58.00 | -- | 0.6517 | -- | -- | -1.87 | -1.87 | 0.00 | 2.03 | 0.00 | -- | -- | 0.00 | -51.80 | -48.56 | -56.80 | -52.09 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 25.02 | -- | -43.53 | -- |
| Milestone Pharmaceuticals Inc | 1.00m | -59.69m | 81.85m | 47.00 | -- | 3.07 | -- | 81.85 | -1.39 | -1.39 | 0.0233 | 0.5009 | 0.0134 | -- | 0.3949 | 21,276.60 | -79.73 | -48.44 | -87.55 | -51.56 | -- | -- | -5,968.50 | -1,267.25 | -- | -- | 0.748 | -- | -80.00 | -- | -2.22 | -- | 86.23 | -- |
| Sellas Life Sciences Group Inc | 0.00 | -37.34m | 82.15m | 16.00 | -- | -- | -- | -- | -1.37 | -1.37 | 0.00 | -0.2482 | 0.00 | -- | -- | 0.00 | -274.94 | -111.48 | -- | -184.29 | -- | -- | -- | -1,289.42 | -- | -- | -- | -- | -100.00 | -- | 9.59 | -- | -- | -- |
| Atara Biotherapeutics Inc | 8.57m | -276.13m | 82.36m | 225.00 | -- | -- | -- | 9.61 | -2.61 | -2.61 | 0.0810 | -0.9322 | 0.0316 | 1.57 | 0.2307 | 38,102.22 | -101.91 | -70.20 | -172.16 | -86.94 | -3.65 | -- | -3,220.88 | -1,559.33 | 0.648 | -- | -- | -- | -86.51 | -- | -20.95 | -- | -49.14 | -- |
| Beyondspring Inc | 1.55m | -27.51m | 82.91m | 67.00 | -- | -- | -- | 53.49 | -0.7043 | -0.7043 | 0.0397 | -0.4637 | 0.0321 | -- | -- | 21,232.88 | -60.79 | -91.82 | -81.96 | -118.82 | -- | -- | -1,895.29 | -9,233.73 | -- | -- | -- | -- | 0.00 | -- | 48.15 | -- | -14.86 | -- |
| Provectus Biopharmaceuticals Inc | 557.71k | -3.10m | 83.28m | 4.00 | -- | -- | -- | 149.32 | -0.0074 | -0.0074 | 0.0013 | -0.0181 | 0.32 | -- | 1,282.09 | 139,427.50 | -177.95 | -276.33 | -- | -- | -- | -- | -556.16 | -1,667.76 | -- | -13.22 | -- | -- | -43.61 | -- | 12.74 | -- | -- | -- |
Data as of Apr 26 2024. Currency figures normalised to Chimerix Inc's reporting currency: US Dollar USD
32.44%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| RA Capital Management LPas of 31 Dec 2023 | 8.80m | 9.86% |
| Monaco Asset Management SAMas of 31 Dec 2023 | 4.38m | 4.91% |
| The Vanguard Group, Inc.as of 31 Dec 2023 | 4.32m | 4.84% |
| Armistice Capital LLCas of 31 Dec 2023 | 2.60m | 2.91% |
| Acadian Asset Management LLCas of 31 Dec 2023 | 1.88m | 2.11% |
| Citadel Advisors LLCas of 31 Dec 2023 | 1.73m | 1.94% |
| Renaissance Technologies LLCas of 31 Dec 2023 | 1.56m | 1.75% |
| Vestal Point Capital LPas of 31 Dec 2023 | 1.40m | 1.57% |
| Goldman Sachs & Co. LLC (Private Banking)as of 31 Dec 2023 | 1.18m | 1.32% |
| Millennium Management LLCas of 31 Dec 2023 | 1.09m | 1.22% |
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
